Key clinical point: Pembrolizumab following locally ablative therapy may improve clinical outcomes in patients with oligometastatic non–small cell lung cancer (NSCLC).
Major finding: Among patients who received pembrolizumab after ablative therapy, the median PFS was 19.1 months (95% confidence interval, 9.4-28.7 months), which was significantly longer than historical outcomes (6.6 months; P = .005).
Study details: A phase 2 study of 51 patients with oligometastatic NSCLC.
Disclosures: The study was funded by the Abramson Cancer Center and Merck & Co. The authors reported financial affiliations with Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Janssen, Takeda, and several others.
Bauml JM et al. JAMA Oncol. 2019 Jul 11. doi: 10.1001/jamaoncol.2019.1449.